SCHEMBL4151496

SCHEMBL4151496

CCC(=O)N(CC(C)C)CC(C)C

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.52
CA12 O43570 3/20 0.52
CA2 P00918 3/20 0.52
CA9 Q16790 3/20 0.52
ALDH1A1 P00352 2/20 0.41
FPR1 P21462 1/20 0.41
HSD17B10 Q99714 1/20 0.41
LMNA P02545 3/20 0.39
FDPS P14324 1/20 0.37
BCHE P06276 1/20 0.37
MLYCD O95822 2/20 0.36
POLB P06746 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19596149 0.86 CA12 (0.45) CA1CA12CA2CA9ALDH1A1
SCHEMBL12600397 0.84 CA12 (0.43) CA1CA12CA2CA9ALDH1A1
SCHEMBL6745240 0.82 TSHR (0.36) CA1CA12CA2CA9ALDH1A1
SCHEMBL20671835 0.81 CA12 (0.41) CA1CA12CA2CA9ALDH1A1
SCHEMBL4146961 0.80 CA1 (0.48) CA1CA12CA2CA9ALDH1A1
SCHEMBL21561630 0.80 CA1 (0.48) CA1CA12CA2CA9ALDH1A1
SCHEMBL20280354 0.80 ALDH1A1 (0.40) CA1CA12CA2CA9ALDH1A1
SCHEMBL17335663 0.80 GGPS1 (0.46) CA1CA12CA2CA9FDPS
SCHEMBL8623620 0.79 CA1 (0.41) CA1CA12CA2CA9ALDH1A1
SCHEMBL17787732 0.79 CA1 (0.52) CA1CA12CA2CA9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11597873-B2 Well treatment compositions and methods comprising certain microemulsions and certain clay control additives exhibiting synergistic effect of enhancing clay swelling protection and persistency FLOTEK CHEMISTRY, LLC (US) 2023-03-07 US disclosed
US-11407930-B2 Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons FLOTEK CHEMISTRY, LLC (US) 2022-08-09 US disclosed
US-20220073812-A1 DILUTED MICROEMULSIONS WITH LOW SURFACE TENSIONS FLOTEK CHEMISTRY, LLC (US) 2022-03-10 US disclosed
US-11254856-B2 Methods and compositions for use in oil and/or gas wells FLOTEK CHEMISTRY, LLC (US) 2022-02-22 US disclosed
US-20210371730-A1 WELL TREATMENT COMPOSITIONS AND METHODS COMPRISING CERTAIN MICROEMULSIONS AND CERTAIN CLAY CONTROL ADDITIVES EXHIBITING SYNERGISTIC EFFECT OF ENHANCING CLAY SWELLING PROTECTION AND PERSISTENCY FLOTEK CHEMISTRY, LLC (US) 2021-12-02 US disclosed
US-11180690-B2 Diluted microemulsions with low surface tensions FLOTEK CHEMISTRY, LLC (US) 2021-11-23 US disclosed
US-20210340435-A1 METHODS AND COMPOSITIONS FOR STIMULATING THE PRODUCTION OF HYDROCARBONS FROM SUBTERRANEAN FORMATIONS FLOTEK CHEMISTRY, LLC (US) 2021-11-04 US disclosed
US-11053433-B2 Methods and compositions for stimulating the production of hydrocarbons from subterranean formations FLOTEK CHEMISTRY, LLC (US) 2021-07-06 US disclosed
US-20210179924-A1 COMPOSITIONS COMPRISING NON-HALOGENATED SOLVENTS FOR USE IN OIL AND/OR GAS WELLS AND RELATED METHODS FLOTEK CHEMISTRY, LLC (US) 2021-06-17 US disclosed
US-11034879-B2 Methods and compositions for use in oil and/or gas wells FLOTEK CHEMISTRY, LLC (US) 2021-06-15 US disclosed
WO-2007020379-A1 IMPROVED CATALYST SYSTEM LUCITE INTERNATIONAL UK LIMITED (GB) 2007-02-22 WO disclosed
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. 2007-01-04 US disclosed
CN-1863456-A Surfactant/solvent mixtures BAYER CROPSCIENCE GMBH (DE) 2006-11-15 CN disclosed
EP-1667519-A1 SURFACTANT/SOLVENT MIXTURES Bayer CropScience GmbH (DE) 2006-06-14 EP disclosed
WO-2005036962-A1 SURFACTANT/SOLVENT MIXTURES BAYER CROPSCIENCE GMBH (DE) 2005-04-28 WO disclosed
US-20050064004-A1 Surfactant/solvent mixtures BAYER CROPSCIENCE GMBH (DE) 2005-03-24 US disclosed
US-6723882-B2 Preparation of dialkyl ketones BASF AKTIENGESELLSCHAFT (DE) 2004-04-20 US disclosed
US-20030069450-A1 Preparation of dialkyl ketones BASF AKTIENGESELLSCHAFT (DE) 2003-04-10 US disclosed
US-4105763-A 1-Methyl-2-(phenyl-oxymethyl)-5-nitro-imidazoles HOECHST AKTIENGESELLSCHAFT (DE) 1978-08-08 US disclosed
US-4078086-A Anthraquinone-bis-amidines and process for preparing them HOECHST AKTIENGESELLSCHAFT (DT) 1978-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling HGF, MET, FLT1 CA1 4780/4885CA12 3912/4885CA2 3271/4885
US-20030069450-A1 Preparation of dialkyl ketones PDK2, PDK3, PDK4 CA1 335/4885CA12 604/4885CA2 1232/4885
US-20050064004-A1 Surfactant/solvent mixtures C1R, C1S, HRH4 CA1 3829/4885CA12 3178/4885CA2 2057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.